A detailed history of Morgan Stanley transactions in Anebulo Pharmaceuticals, Inc. stock. As of the latest transaction made, Morgan Stanley holds 399,219 shares of ANEB stock, worth $582,859. This represents 0.0% of its overall portfolio holdings.

Number of Shares
399,219
Previous 399,219 -0.0%
Holding current value
$582,859
Previous $1.09 Million 29.29%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 13, 2024

BUY
$1.71 - $3.17 $682,664 - $1.27 Million
399,219 New
399,219 $966,000
Q3 2022

Nov 14, 2022

BUY
$2.8 - $5.49 $1,680 - $3,294
600 New
600 $2,000
Q2 2022

Aug 15, 2022

SELL
$2.7 - $7.15 $8 - $21
-3 Closed
0 $0
Q1 2022

Oct 27, 2022

BUY
$6.0 - $7.7 $18 - $23
3 New
3 $0
Q1 2022

May 13, 2022

BUY
$6.0 - $7.7 $6 - $7
1 Added 50.0%
3 $0
Q4 2021

Feb 14, 2022

BUY
$5.84 - $7.3 $11 - $14
2 New
2 $0

Others Institutions Holding ANEB

About Anebulo Pharmaceuticals, Inc.


  • Ticker ANEB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,633,200
  • Market Cap $37.4M
  • Description
  • Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The ...
More about ANEB
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.